Mahesh Patel - Lipocine Co-Founder, Chairman, CEO and Pres
| LPCN Stock | USD 3.63 0.09 2.54% |
Chairman
Dr. Mahesh V. Patel, Ph.D., is Chairman of the Board, President, Chief Executive Officer of Lipocine Inc. He has served as Company President and Chief Executive Officer since 1997 and as a member of Company Board of Directors since 1997. Dr. Patel has more than 25 years of experience in strategic planning, technology assessment development, technical management and product research and development in the area of drug discovery support, drug delivery and product line extensions. Prior to cofounding Lipocine in 1997, he led drug delivery research and development at Pharmacia and Upjohn since 2014.
| Age | 68 |
| Tenure | 11 years |
| Address | 675 Arapeen Drive, Salt Lake City, UT, United States, 84108 |
| Phone | 801 994 7383 |
| Web | https://www.lipocine.com |
Mahesh Patel Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mahesh Patel against Lipocine stock is an integral part of due diligence when investing in Lipocine. Mahesh Patel insider activity provides valuable insight into whether Lipocine is net buyers or sellers over its current business cycle. Note, Lipocine insiders must abide by specific rules, including filing SEC forms every time they buy or sell Lipocine'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mahesh Patel over a month ago Acquisition by Mahesh Patel of 16371 shares of Lipocine at 4.86 subject to Rule 16b-3 | ||
Mahesh Patel over three months ago Acquisition by Mahesh Patel of 21928 shares of Lipocine at 0.428 subject to Rule 16b-3 | ||
Mahesh Patel over six months ago Acquisition by Mahesh Patel of 50000 shares of Lipocine at 0.7699 subject to Rule 16b-3 | ||
Mahesh Patel over a year ago Exercise or conversion by Mahesh Patel of 145000 shares of Lipocine subject to Rule 16b-3 |
Lipocine Management Efficiency
The company has return on total asset (ROA) of (0.1456) % which means that it has lost $0.1456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.195) %, meaning that it created substantial loss on money invested by shareholders. Lipocine's management efficiency ratios could be used to measure how well Lipocine manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of February 2025, Return On Tangible Assets is likely to grow to -0.78. In addition to that, Return On Capital Employed is likely to drop to -0.83. At this time, Lipocine's Total Assets are very stable compared to the past year. As of the 16th of February 2025, Other Assets is likely to grow to about 4 M, while Net Tangible Assets are likely to drop about 27 M.Similar Executives
| Found 4 records | CHAIRMAN Age | ||
| John CPA | Hepion Pharmaceuticals | 77 | |
| Michael Esq | Mustang Bio | 59 | |
| Lindsay Rosenwald | Fortress Biotech Pref | 68 | |
| Stephen Glover | ZyVersa Therapeutics | 65 | |
Management Performance
| Return On Equity | -0.19 | ||||
| Return On Asset | -0.15 |
Lipocine Leadership Team
Elected by the shareholders, the Lipocine's board of directors comprises two types of representatives: Lipocine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lipocine. The board's role is to monitor Lipocine's management team and ensure that shareholders' interests are well served. Lipocine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lipocine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Co Sec | ||
| Logan Morse, Marketing Sales | ||
| Nachiappan Chidambaram, Senior Development | ||
| M MD, Chief Director | ||
| Mahesh Patel, Co-Founder, Chairman, CEO and Pres | ||
| Krista Fogarty, Principal Controller | ||
| MD D, Chief Director |
Lipocine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lipocine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.19 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.51) % | ||||
| Operating Margin | (0.67) % | ||||
| Current Valuation | (410.61 K) | ||||
| Shares Outstanding | 5.35 M | ||||
| Shares Owned By Insiders | 2.91 % | ||||
| Shares Owned By Institutions | 9.16 % | ||||
| Number Of Shares Shorted | 77.74 K | ||||
| Price To Earning | 15.80 X |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.75) | Revenue Per Share | Quarterly Revenue Growth 137.519 | Return On Assets | Return On Equity |
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.